Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

LBH 589

"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"

DRUG

Pemetrexed

Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Pittsburgh

OTHER